Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6+cetuximab (FX plus C) or FOLFIRI plus cetuximab (FF plus C): The CECOG/CORE1.2.001 trial

被引：0
|
作者：
Koza, I., Sr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wrba, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Vrbanec, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Ocvirk, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Ciuleanu, T. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Beslija, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Papamichael, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Messinger, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Zielinski, C. C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Brodowicz, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] NCI, Bratislava, Slovakia
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Hosp Rebro, Zagreb, Croatia
[4] Inst Oncol, Ljubljana, Slovenia
[5] Univ Med Cluj Napoca, Cluj Napoca, Romania
[6] Univ Sarajevo, Ctr Clin, Sarajevo 71000, Bosnia & Herceg
[7] Bank Cyprus Oncol Ctr, Nicosia, Cyprus
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4055
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Cetuximab plus Xeliri versus cetuximab plus xelox as first-line treatment of patients with metastatic colorectal cancer (MCRC): A randomised trial of the German Aid CRC study group
    Heinernann, V
    Fischer, Von Weikersthal L.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 13 - 13
  • [22] RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
    Normanno, N.
    Abate, R. Esposito
    Lambiase, M.
    Forgione, L.
    Cardone, C.
    Iannaccone, A.
    Sacco, A.
    Rachiglio, A. M.
    Martinelli, E.
    Rizzi, D.
    Pisconti, S.
    Biglietto, M.
    Bordonaro, R.
    Troiani, T.
    Latiano, T. P.
    Giuliani, F.
    Leo, S.
    Rinaldi, A.
    Maiello, E.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 112 - 118
  • [23] Analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC)
    Stintzing, S.
    Jung, A.
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H.
    von Weikersthal, Fischer L.
    Moosmann, N.
    Kirchner, T.
    Heinemann, V
    ONKOLOGIE, 2010, 33 : 226 - 226
  • [24] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    De Braud, F. G.
    Volovat, C.
    Nippgen, J.
    Stroh, C.
    Celik, I.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - an interim analysis of the CEBIFOX trial
    Hoehler, T.
    Decker, T.
    Schimanski, C.
    Schmitz, S.
    Kanzler, S.
    Rauh, J.
    Vehling-Kaiser, U.
    Bernhard, H.
    Hoffmann, T.
    Niederle, N.
    von Verschuer, U.
    von Wichert, G.
    Wagner, T.
    Klein, M.
    ONKOLOGIE, 2013, 36 : 105 - 105
  • [26] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306
    Stintzing, S.
    Neumann, J.
    Jung, A.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Jaeger, E.
    Heintges, T.
    Stoll, C.
    Modest, D. P.
    Kirchner, T.
    Scheithauer, W.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] ANALYSIS OF MOLECULAR ALTERATIONS FOR PREDICTING CLINICAL BENEFIT TO CETUXIMAB PLUS CHEMOTHERAPY IN FIRST-LINE METASTATIC COLORECTAL CANCER (MCRC)
    Javier, Sastre
    Patricia, Llovet
    Julian, Sanz
    Inmaculada, Bando
    Milagros, Ferrer
    Alfonso Pilar, Garcia
    Olga, Donnay
    Alfredo, Carrato
    Ana, Jimenez-Gordo
    Enrique, Aranda
    Ana, Leon
    Cristina, Gravalos
    Juan Carlos, Camara
    Jaime, Feliu
    Beatriz, Sanchiz
    Trinidad, Caldes
    Eduardo, Diaz-Rubio
    ANNALS OF ONCOLOGY, 2014, 25
  • [28] Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).
    Moosmann, N.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Dietzfelbinger, H. F.
    Oruzio, D. V.
    Klein, S.
    Stintzing, S.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: The FIRE-3 trial (AIO KRK 0307)
    Heinemann, V
    von Weikersthal, Fischer L.
    Decker, T.
    Kiani, A.
    Verhling-Kaiser, U.
    Al Batran, S.
    Heintges, T.
    Lerchenmueller, C.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Stauch, M.
    Scheithauer, W.
    Hielscher, J.
    Scholz, M.
    Mueller, S.
    Schaefer, B.
    Moehler, M.
    Modest, D. P.
    Jung, A.
    Stintzing, S.
    ONKOLOGIE, 2013, 36 : 104 - 104
  • [30] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hoehler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Ting, Saskia
    Markus, Peter
    Paul, Andreas
    Schuler, Martin H.
    Trarbach, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345